North America Influenza Vaccines Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Vaccine Type, Virus Type, Technology, and Route of Administration

List of Tables

The North America influenza vaccines market is expected to grow from US$ 3,155.29 million in 2022 to US$ 4,909.00 million by 2028; it is estimated to grow at a CAGR of 7.6% from 2022 to 2028.

Increase in Government Support to Promote Influenza Vaccination Boosts North America Influenza Vaccines Market

Several governments of North American countries are supporting the promotion of vaccination through multiple activities and programs. By 2022, enough vaccines have been secured to cover all risk groups eligible for a government-funded flu vaccine through the National Immunisation Program (NIP). A few more instances of government support for influenza vaccination include: In July 2022, Public Services and Procurement Minister Filomena Tassi and Health Minister Jean-Yves Duclos announced that the Government of Canada had signed a new contract with GlaxoSmithKline (GSK) to support a sustainable influenza pandemic readiness. The Government of Canada maintains pandemic influenza vaccine preparedness in the event of an influenza pandemic. It has had a contract with GSK to provide seasonal and pandemic influenza vaccines since 2001. Pandemic influenzas are unpredictable but occur when a new strain of influenza virus emerges, spreads widely, and causes the disease. In July 2022, Seniors and Long-term Care Minister Scott Johnston and Health Minister Audrey Gordon announced that the Manitoba government would expand the high-dose flu vaccine eligibility to include all adults aged 65 and over to ensure that more of the Manitoba population is protected against influenza. The Victorian government proposed a grant and reimbursement program to help GPs and pharmacies improve access and uptake of the influenza vaccines by June and July 2022. In September 2019, the former US President Donald Trump signed an executive order to promote the development of better vaccines against seasonal flu and the potential for pandemic flu outbreaks. In October 2021, the Provincial Government encouraged all Newfoundlanders and Labradorians to get a flu shot. From October 25, 2021, the Regional Health Authorities (RHAs) have begun hosting free flu vaccination clinics. Thus, increasing government support to promote the influenza vaccination is driving the North America influenza vaccines market.

North America Influenza Vaccines Market Overview

The North America influenza vaccines market is segmented into the US, Canada, and Mexico. The US held the largest share of the market in 2022. The rising number of flu cases, growing research & development activities on flu vaccines, and increasing demand for advanced vaccines to prevent diseases are among the prominent factors propelling the market growth in this region.

North America Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Million)

North America Influenza Vaccines Market Segmentation

The North America influenza vaccines market is segmented on the basis of vaccine type, virus type, technology, route of administration, target group, and country.

Based on vaccine type, the North America influenza vaccines market is bifurcated into quadrivalent vaccines and trivalent vaccines. The quadrivalent vaccines segment registered a larger share of the market in 2022.

Based on virus type, the North America influenza vaccines market is bifurcated into influenza virus type A and influenza virus type B. The influenza virus type A segment held a larger share of the market in 2022.

Based on technology, the North America influenza vaccines market is divided into egg-based and cell-based. The egg-based segment held a larger share of the market in 2022.

Based on route of administration, the North America influenza vaccines market is divided into injection and nasal spray. The injection segment held a larger share of the market in 2022.

Based on target group, the North America influenza vaccines market is segmented into infants, children, adults, and elderly people. The infants segment held the largest share of the market in 2022.

Based on country, the North America influenza vaccines market is segmented into the US, Mexico, and Canada. The US dominated the market in 2022.

AstraZeneca; Emergent BioSolutions Inc.; GlaxoSmithKline plc.; Mitsubishi Chemical Group Corporation; Moderna, Inc.; MYLAN N.V.; Sanofi; SEQIRUS; and Serum Institute of India Pvt. Ltd are the leading companies operating in the North America influenza vaccines market.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America influenza vaccines market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in North America influenza vaccines market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth North America market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution

Product Code: BMIRE00026961

1. Introduction

1.1 Study Scope
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
- 1.3.1 North America Influenza Vaccines Market - By Vaccine Type
- 1.3.2 North America Influenza Vaccines Market - By Virus Type
- 1.3.3 North America Influenza Vaccines Market - By Technology
- 1.3.4 North America Influenza Vaccines Market - By Route of Administration
- 1.3.5 North America Influenza Vaccines Market - By Target Group
- 1.3.6 North America Influenza Vaccines Market - By Country

2. North America Influenza Vaccines Market - Key Takeaways

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. North America Influenza Vaccines Market - Market Landscape

4.1 Overview
4.2 PEST Analysis
- 4.2.1 North America PEST Analysis
4.3 Experts Opinion

5. North America Influenza Vaccines Market - Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Increase in Government Support to Promote Influenza Vaccination
- 5.1.2 Increasing Investment by Top Market Players and Governments
5.2 Market Restraints
- 5.2.1 High Cost of Vaccine Development
5.3 Market Opportunities
- 5.3.1 Emerging Economies
5.4 Future Trends
- 5.4.1 Strong Pipeline Candidates for Influenza Vaccines
5.5 Impact Analysis

6. Influenza Vaccine Market -North America Analysis

6.1 North America Influenza Vaccines Market, By Country - Forecasts And Analysis
6.2 North America Influenza Vaccines Market Revenue Forecasts And Analysis - 2020- 2028 (US$ Mn)
- 6.2.1 North America: Influenza Vaccines Market, 2019-2028 (US$ Million)

7. North America Influenza Vaccines Market Analysis and Forecasts To 2028 - By Vaccine Type

7.1 Overview
7.2 North America Influenza Vaccines Market, By Vaccine Type 2022 & 2028 (%)
- 7.2.1 North America: Influenza Vaccines Market, by Vaccine Type, 2019-2028 (US$ Million)
7.3 Quadrivalent Vaccines
- 7.3.1 Overview
- 7.3.2 Quadrivalent Vaccines : North America Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)
7.4 Trivalent Vaccines
- 7.4.1 Overview
- 7.4.2 Trivalent Vaccines : North America Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)

8. North America Influenza Vaccines Market Analysis and Forecasts To 2028 - By Virus Type

8.1 Overview
8.2 North America Influenza Vaccines Market, By Virus Type 2022 & 2028 (%)
- 8.2.1 North America: Influenza Vaccines Market, by Virus Type, 2019-2028 (US$ Million)
8.3 Influenza Virus Type A
- 8.3.1 Overview
- 8.3.2 Influenza Virus Type A : North America Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)
8.4 Influenza Virus Type B
- 8.4.1 Overview
- 8.4.2 Influenza Virus Type B : North America Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)

9. North America Influenza Vaccines Market Analysis and Forecasts To 2028 - By Technology

9.1 Overview
9.2 North America Influenza Vaccines Market, By Technology 2022 & 2028 (%)
- 9.2.1 North America: Influenza Vaccines Market, by Technology, 2019-2028 (US$ Million)
9.3 Egg-based
- 9.3.1 Overview
- 9.3.2 Egg-based : North America Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)
9.4 Cell-based
- 9.4.1 Overview
- 9.4.2 Cell-Based : North America Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)

10. North America Influenza Vaccines Market Analysis and Forecasts To 2028 - By Route of Administration

10.1 Overview
10.2 North America Influenza Vaccines Market, By Route of Administration 2022 & 2028 (%)
- 10.2.1 North America: Influenza Vaccines Market, by Route of Administration, 2019-2028 (US$ Million)
10.3 Injection
- 10.3.1 Overview
- 10.3.2 Injection : North America Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)
10.4 Nasal Spray
- 10.4.1 Overview
- 10.4.2 Nasal Spray: North America Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)

11. North America Influenza Vaccines Market Analysis and Forecasts To 2028 - By Target Group

11.1 Overview
11.2 North America Influenza Vaccines Market, By Target Group 2022 & 2028 (%)
- 11.2.1 North America: Influenza Vaccines Market, by Target Group, 2019-2028 (US$ Million)
11.3 Infants
- 11.3.1 Overview
- 11.3.2 Infants : North America Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)
11.4 Children
- 11.4.1 Overview
- 11.4.2 Children: North America Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)
11.5 Adults
- 11.5.1 Overview
- 11.5.2 Adults : North America Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)
11.6 Elderly People
- 11.6.1 Overview
- 11.6.2 Elderly People: North America Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)

12. North America Influenza Vaccines Market Analysis and Forecasts To 2028 - Country Analysis

12.1 North America Influenza Vaccines Market Revenue and Forecasts To 2028
- 12.1.1 Overview
- 12.1.2 North America: Influenza Vaccines Market, by Country, 2022 & 2028 (%)
  - 12.1.2.1 US: Influenza Vaccines Market - Revenue and Forecast to 2028 (US$ Million)
    - 12.1.2.1.1 Overview
    - 12.1.2.1.2 US: Influenza Vaccines Market - Revenue and Forecast to 2028 (US$ Million)
    - 12.1.2.1.3 US: Influenza Vaccines Market, by Vaccine Type, 2019-2028 (US$ Million)
    - 12.1.2.1.4 US: Influenza Vaccines Market, by Virus Type, 2019-2028 (US$ Million)
    - 12.1.2.1.5 US: Influenza Vaccines Market, by Technology, 2019-2028 (US$ Million)
    - 12.1.2.1.6 US: Influenza Vaccines Market, by Route of Administration, 2019-2028 (US$ Million)
    - 12.1.2.1.7 US: Influenza Vaccines Market, by Target Group, 2019-2028 (US$ Million)
  - 12.1.2.2 Canada: Influenza Vaccines Market - Revenue and Forecast to 2028 (US$ Million)
    - 12.1.2.2.1 Overview
    - 12.1.2.2.2 Canada: Influenza Vaccines Market - Revenue and Forecast to 2028 (US$ Million)
    - 12.1.2.2.3 Canada: Influenza Vaccines Market, by Vaccine Type, 2019-2028 (US$ Million)
    - 12.1.2.2.4 Canada: Influenza Vaccines Market, by Virus Type, 2019-2028 (US$ Million)
    - 12.1.2.2.5 Canada: Influenza Vaccines Market, by Technology, 2019-2028 (US$ Million)
    - 12.1.2.2.6 Canada: Influenza Vaccines Market, by Route of Administration, 2019-2028 (US$ Million)
    - 12.1.2.2.7 Canada: Influenza Vaccines Market, by Target Group, 2019-2028 (US$ Million)
  - 12.1.2.3 Mexico: Influenza Vaccines Market - Revenue and Forecast to 2028 (US$ Million)
    - 12.1.2.3.1 Overview
    - 12.1.2.3.2 Mexico: Influenza Vaccines Market - Revenue and Forecast to 2028 (US$ Million)
    - 12.1.2.3.3 Mexico: Influenza Vaccines Market, by Vaccine Type, 2019-2028 (US$ Million)
    - 12.1.2.3.4 Mexico: Influenza Vaccines Market, by Virus Type, 2019-2028 (US$ Million)
    - 12.1.2.3.5 Mexico: Influenza Vaccines Market, by Technology, 2019-2028 (US$ Million)
    - 12.1.2.3.6 Mexico: Influenza Vaccines Market, by Route of Administration, 2019-2028 (US$ Million)
    - 12.1.2.3.7 Mexico: Influenza Vaccines Market, by Target Group, 2019-2028 (US$ Million)

13. North America Influenza Vaccine Market -Industry Landscape

13.1 Overview
13.2 Growth Strategies in the Influenza Vaccine Market, 2021-2028
13.3 Inorganic Growth Strategies
- 13.3.1 Overview
13.4 Organic Growth Strategies
- 13.4.1 Overview

14. Company Profiles

14.1 Moderna, Inc.
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 SEQIRUS
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 Sanofi
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
14.4 GlaxoSmithKline plc.
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
14.5 Emergent BioSolutions Inc.
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
14.6 Mitsubishi Chemical Group Corporation
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
14.7 Serum Institute of India Pvt. Ltd
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
14.8 MYLAN N.V.
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
14.9 AstraZeneca
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments

15. Appendix

15.1 About The Insight Partners
15.2 Glossary of Terms